Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SURF
- 08 Mar 2018 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
- 08 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 26 Feb 2016 New trial record